LAG3 study in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is studying a protein called LAG3 in triple-negative breast cancer. It is for people who will receive chemotherapy before surgery to see if LAG3 levels affect how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are planning to have chemotherapy before surgery (neoadjuvant).
- You have been diagnosed with triple-negative breast cancer.
- Your cancer is not HER2-positive.
- Your cancer is not hormone receptor-positive (estrogen or progesterone receptors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This study looks at how your immune system responds to triple-negative breast cancer. It will test your blood or tissue to learn more about your body's natural defenses against the cancer.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.